Fresenius Kabi AG
Division of Fresenius SE & Co. KGaA
www.fresenius-kabi.com
Latest From Fresenius Kabi AG
US Appeal Against 2021 Cabazitaxel Patent Falls Flat
An attempt by Accord, Actavis, Apotex, Kabi and Mylan to overturn a US patent protecting Sanofi’s Jevtana cabazitaxel cancer drug until 2021 has failed. And claims in a patent running until 2031 could yet return to haunt the generics firms.
Kabi Is Ready To Get More Aggressive On US Market Share
With supply shortages easing and a period of channel destocking largely over, Fresenius Kabi’s US injectables business is preparing to fight hard to maintain its market position, group CEO Stephan Sturm says.
Amgen’s Nonconformist Position On Biosimilar Payment Policy Reflects Market Strategy
Company objects to legislative proposals that would enhance Medicare Part B reimbursement for biosimilars to boost uptake, even as it launches its first biosimilars in the US market.
EU Biosimilar Filings, Opinions And Approvals
A list of new EU biosimilar product filings, CHMP opinions and marketing authorizations issued by the European Commission. The updated list includes the filing of the first biosimilar version of insulin aspart and the approval of the EU’s sixth biosimilar pegfilgrastim product.
Company Information
- Industry
-
Medical Devices
- Infusion Therapy Equipment and Supplies
-
Pharmaceuticals
- Generic Drugs
- Therapeutic Areas
- Non-Specific
- Alias(es)
- Ownership
- Private
- Headquarters
-
Worldwide
-
Europe
-
Western Europe
-
Germany
-
Germany
-
Western Europe
-
Europe
- Parent & Subsidiaries
- Fresenius SE & Co. KGaA
- Senior Management
- Rainer Baule, Chmn. & CEO
- Contact Info
-
Fresenius Kabi AG
Phone: (49) 6172 686 0
Else-Kröner-Straße 1
Bad Homburg , 61352
Germany
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice